Product Usage: This PRODUCT IS INTENDED AS A RESEARCH CHEMICAL ONLY. This designation allows the use of research chemicals strictly for in vitro testing and laboratory experimentation only.All product information available on this website is for educational purposes only. Bodily introduction of any kind into humans or animals is strictly forbidden by law. This product should only be handled by licensed, qualified professionals. This product is not a drug, food, or cosmetic and may not be misbranded, misused or mislabeled as a drug, food or cosmetic.

Ipamorelin_10MG

Ipamorelin

Ipamorelin is a synthetic growth hormone–releasing peptide (GHRP) designed to selectively interact with the growth hormone secretagogue receptor (GHS-R). In laboratory research, ipamorelin is utilized as a research reagent for studying receptor-mediated signaling, growth hormone release dynamics, and comparative structure–activity relationships within the GHRP class under controlled experimental conditions.*

Unlike earlier GHRPs, ipamorelin has been extensively examined in research models for its selective receptor activation profile, making it a useful tool for investigations focused on endocrine signaling specificity and downstream intracellular pathways.*

  • Peptide Name: Ipamorelin
  • Peptide Class: Growth Hormone–Releasing Peptide (GHRP)
  • Amino Acid Length: 5 amino acids
  • Form: Lyophilized powder
  • Purity: ≥99% (HPLC verified)
  • Quantity: 5 mg per vial
  • Analytical Verification: HPLC and Mass Spectrometry (MS)
  • Manufacturing: Synthesized and quality-tested under controlled laboratory conditions
  • Designation: For Research Use Only (RUO)

$80.00

$76.00 each
$72.00 each

Products will arrive in a lyophilized (powder) form for maximum stability.

Free domestic shipping on orders over $300

Ipamorelin

Scientific & Research Context

Ipamorelin has been studied in published research for its interaction with the GHS-R and its ability to stimulate growth hormone release in experimental systems without significant activation of other pituitary hormones in comparative models.* These characteristics have made ipamorelin a frequent subject in endocrine signaling and peptide receptor research.*

In laboratory settings, ipamorelin has been examined in relation to:*

  • Growth hormone secretagogue receptor activation studies*
  • Hypothalamic–pituitary axis signaling models*
  • Peptide–receptor binding and affinity assays*
  • Comparative GHRP structure–activity research*
  • Neuroendocrine and intracellular signaling pathways*

Its defined structure and selective activity profile make ipamorelin a valuable tool in mechanistic studies involving growth hormone regulation.*

Quality & Analytical Assurance

Each batch of ipamorelin undergoes rigorous analytical testing to confirm molecular identity, sequence integrity, and purity. Verification using validated HPLC and MS methodologies ensures batch-to-batch consistency and reproducibility across research applications.

Storage & Handling

Ipamorelin is supplied in lyophilized form to enhance stability during storage and transport. Store unopened vials in a cool, dry environment protected from light. Reconstitution and handling should follow established peptide research and laboratory best practices to preserve molecular integrity.

For further information on proper storage techniques, click the button…

Storage Instructions

Referenced Scientific Literature
Provided for informational and educational purposes only

  • Raun K, et al. Ipamorelin, a novel growth hormone secretagogue, selectively stimulates growth hormone release in vitro and in vivo. Journal of Endocrinology, 1995; 147(3): 441–449.
  • Raun K, et al. Comparison of the effects of GHRP-6, hexarelin, and ipamorelin on growth hormone release in rats. Endocrinology, 1996; 137(9): 3864–3871.
  • Raun K, et al. Ipamorelin, the first selective growth hormone secretagogue. European Journal of Endocrinology, 1998; 139(5): 552–561.
  • Camanni F, et al. Growth hormone–releasing activity of ipamorelin in humans. Journal of Clinical Endocrinology & Metabolism, 1998; 83(2): 353–358.
  • Arvat E, et al. Selective stimulation of growth hormone secretion by ipamorelin in comparison with other growth hormone secretagogues. Journal of Endocrinological Investigation, 1997; 20(7): 407–412.
  • Ghigo E, Arvat E, Broglio F, Gianotti L. Growth hormone secretagogues: physiological and pharmacological aspects. Baillière’s Clinical Endocrinology and Metabolism, 1998; 12(2): 297–310.
  • Howard AD, et al. A receptor in pituitary and hypothalamus that functions in growth hormone release. Science, 1996; 273(5277): 974–977.
  • Smith RG, et al. Peptidomimetic regulation of growth hormone secretion. Endocrine Reviews, 1997; 18(5): 621–645.
  • Van der Lely AJ, Tschöp M, Heiman ML, Ghigo E. Biological, physiological, pathophysiological, and pharmacological aspects of ghrelin. Endocrine Reviews, 2004; 25(3): 426–457.
  • Muccioli G, et al. Growth hormone secretagogues and the cardiovascular system. Journal of Endocrinological Investigation, 2000; 23(10): 698–705.
  • Andersen NB, Malmlöf K, Johansen PB, Andreassen TT, Ørtoft G, Oxlund H. Ipamorelin counteracts glucocorticoid-induced decrease in bone formation in adult rats. Growth Hormone & IGF Research, 2001; 11(5): 266–272.
  • Svensson J, et al. Ipamorelin and GHRP-6 increase bone mineral content in adult female rats. Journal of Endocrinology, 2000; 165(3): 569–577.
  • Aagaard NK, et al. Growth hormone and growth hormone secretagogue effects on nitrogen balance in steroid-treated rats. Growth Hormone & IGF Research, 2009; 19(5): 426–431.
  • Adeghate E, Ponery AS. Mechanism of ipamorelin-evoked insulin release from the pancreas of normal and diabetic rats. Neuroendocrinology Letters, 2004; 25(6): 403–406.
  • Beck DE, et al. Proof-of-concept study of the ghrelin mimetic ipamorelin for management of postoperative ileus. International Journal of Colorectal Disease, 2014; 29(12): 1527–1534.
  • Greenwood-Van Meerveld B, et al. Efficacy of ipamorelin on gastric dysmotility in a rodent model of postoperative ileus. Journal of Experimental Pharmacology, 2012; 4: 149–155.
  • Fowkes MM, et al. Peptidomimetic growth hormone secretagogue derivatives for PET imaging of the ghrelin receptor. European Journal of Medicinal Chemistry, 2018; 157: 1500–1511.

ALL ARTICLES AND PRODUCT INFORMATION PROVIDED ON THIS WEBSITE ARE FOR INFORMATIONAL AND EDUCATIONAL PURPOSES ONLY. The products offered on this website are furnished for in-vitro studies only. In-vitro studies (Latin: in glass) are performed outside of the body. These products are not medicines or drugs and have not been approved by the FDA to prevent, treat or cure any medical condition, ailment or disease. Bodily introduction of any kind into humans or animals is strictly forbidden by law.